BibTex format
@article{Bloch:2024:10.1038/s41440-024-01854-w,
author = {Bloch, MJ and Kirtane, AJ and Azizi, M and Mahfoud, F and Basile, J and Daemen, J and Saxena, M and Thackeray, L and McGuire, M and Claude, L and Schmieder, RE and RADIANCE-HTN, Investigators},
doi = {10.1038/s41440-024-01854-w},
journal = {Hypertens Res},
pages = {3467--3472},
title = {36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.},
url = {http://dx.doi.org/10.1038/s41440-024-01854-w},
volume = {47},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.
AU - Bloch,MJ
AU - Kirtane,AJ
AU - Azizi,M
AU - Mahfoud,F
AU - Basile,J
AU - Daemen,J
AU - Saxena,M
AU - Thackeray,L
AU - McGuire,M
AU - Claude,L
AU - Schmieder,RE
AU - RADIANCE-HTN,Investigators
DO - 10.1038/s41440-024-01854-w
EP - 3472
PY - 2024///
SP - 3467
TI - 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.
T2 - Hypertens Res
UR - http://dx.doi.org/10.1038/s41440-024-01854-w
UR - https://www.ncbi.nlm.nih.gov/pubmed/39333663
VL - 47
ER -